Loading
A fourth-generation ALK pill that works after lorlatinib and avoids the TRK-related brain side effects; under FDA priority review with a decision due 27 November 2026.
Nuvalent's ALK-selective, TRK-sparing, brain-penetrant inhibitor covering G1202R and compound mutations. ALKOVE-1: ORR 31% in heavily TKI-pretreated patients (n=253) with intracranial activity. NDA submitted April 2026 (priority review, PDUFA 27 Nov 2026). ALKAZAR phase 3 vs alectinib first line recruiting.
ALK-selective TKI designed to avoid TRK inhibition (dizziness, weight gain) and cover solvent-front and compound mutations. Connects to ALK.
1.Neladalkib slips into a pocket on ALK.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Neladalkib" OR ABSTRACT:"Neladalkib" OR TITLE:"NVL-655" OR ABSTRACT:"NVL-655") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Neladalkib, not a curated reading list.
Shares Alectinib, ALK-positive non-small-cell lung cancer, ALK, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Alectinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lorlatinib, ALK-positive non-small-cell lung cancer, ALK, Non-small-cell lung cancer.
Shares Alectinib, ALK-positive non-small-cell lung cancer, ALK, Small-molecule kinase inhibitors.